For AFT Pharmaceuticals, selling and licensing a non-addictive pain relief medication in markets that are finally grappling with who bears the blame for the opioid crisis is a double-edged sword.
Founder and managing director Dr Hartley Atkinson said his company’s non-addictive alternative
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
